Details for Patent: 8,846,618

Which drugs does patent 8,846,618 protect, and when does it expire?

Patent 8,846,618 protects SAXENDA and VICTOZA and is included in two NDAs.

Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eleven patent family members in nine countries.

Summary for Patent: 8,846,618

Title:	Stable formulation of modified GLP-1
Abstract:	Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.
Inventor(s):	Flink; James M. (Klanpenborg, DK), Larsen; Silke Moller (Charlottenlund, DK), Jensen; Simon Bjerregaard (Frederiksberg, DK), Engelund; Dorthe Kot (Holte, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	12/785,861
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,846,618
Patent Claim Types: see list of patent claims	Formulation; Compound; Use;

Drugs Protected by US Patent 8,846,618

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes					Y
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,846,618

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2001 01010	Jun 28, 2001
Denmark	2001 01011	Jun 28, 2001
Denmark	2001 01052	Jul 4, 2001
Denmark	2001 01053	Jul 4, 2001
Denmark	2002 00093	Jan 18, 2002

International Family Members for US Patent 8,846,618

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	382057
Australia	2002316811
Germany	60224284
Denmark	1412384
European Patent Office	1412384
Spain	2298378